Apologies for wasting your time
@Taureanbull but I would note that just because management performed initially in securing creditable IP, doesn't in any way constitute ongoing or indeed future success. I stand by my initial posts given the extremely promising pre clinical data and huge unmet need Imugenes treatment arms aimed to address. Not to forget the brilliant scientists they brought on board to develop their novel and innovative treatment arms. Unfortunately the Board and Managements failure to secure one commercial outcome be it in the form of a partnership deal, JV or anything of that ilk, despite having so many shots on goal, is undeniable. Added to which managements poor handling of what was an outstanding B cell platform is there for all to see. Her Vaxx and PD1 Vaxx either as combinations or stand alone treatments should be much further down the track than they are today.
Contrary to your contrite assessment of MSNBC, with over 40 years experience investment experience I believe I am highly qualified to make such opinions. It would be safe to say I have performed as much research as anyone, including you, on this stock and its participants and contributors, both online and in person. Whilst presenting a balanced opinion clearly offends you, I believe it is in the best interest of readers to tell how it is, at any given point in time. There is undoubtedly plenty of blue sky with Imugene. But clearly unlike you I believe Imugene's best course of action is with the support, financial veracity and market share from a larger player, such as a Big Pharma. Until they incept such a position, I again unlike you, see it as being a slow boat to China when it comes to the Imugene train.
As far as personal investment plays I am not blaming management of anyone for my own decisions. And btw I am by no means angry, simply frustrated, as the majority of us are at the failure of management to deliver capital growth for shareholders. But yes I still hold out hope Imugene's science shall play a pivotal role in treating solid tumours and potentially blood cancers in years to come. Whilst as far as the book goes, it's still a good read, though I would note not all chapters need to be rosy. For it wouldn't be much of a story if everything went to plan.
Opinions only
(20min delay)